Literature DB >> 17382304

Effect of the selective dopamine D3 receptor antagonist SB-277011-A on regional c-Fos-like expression in rat forebrain.

Eric Southam1, Andrew Lloyd, Carol A Jennings, Jane E Cluderay, Jackie Cilia, Jane E Gartlon, Declan N C Jones.   

Abstract

SB-277011-A is a dopamine D(3) receptor antagonist that exhibits over 100-fold selectivity over dopamine D(2) receptors and a broad spectrum of other receptor, ion channels, and enzymes. We employed c-Fos immunohistochemistry to characterise the functional neuroanatomical effects of acute administration of SB-277011-A and observed a time-dependent increase in the density of c-Fos-like positive nuclei in rat forebrain with maximal effects observed 2 h post-dose. The relative influence of the different brain regions on the overall effect of SB-277011-A was ranked by partial least squares discriminant analysis loadings plot which indicated that sites within the nucleus accumbens exerted the greatest influence on the separation of the vehicle and SB-277011-A treatment groups. At the 2 h time-point, c-Fos-like expression was shown to be significantly elevated (p<0.05) in the core and shell of the nucleus accumbens, at both rostral and caudal levels, and in the lateral septum. No significant changes were detected in the caudate nucleus (lateral or medial) or in the cingulate, infralimbic prefrontal, or somatosensory cortices. The capacity of SB-277011-A to trigger immediate early gene expression in these limbic regions of rat brain adds to a growing consensus of the potential utility of dopamine D(3) receptor antagonism in psychiatric disorders including schizophrenia and drug dependency.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17382304     DOI: 10.1016/j.brainres.2007.02.051

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  Alterations in postnatal neurogenesis and dopamine dysregulation in schizophrenia: a hypothesis.

Authors:  Dragos Inta; Andreas Meyer-Lindenberg; Peter Gass
Journal:  Schizophr Bull       Date:  2010-11-19       Impact factor: 9.306

Review 2.  Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction.

Authors:  Bernard Le Foll; Patricia Di Ciano
Journal:  Eur Neuropsychopharmacol       Date:  2014-09-16       Impact factor: 4.600

3.  Fos expression in response to dopamine D3-preferring phenylpiperazine drugs given with and without cocaine.

Authors:  Brian C Nolan; Shinban Liu; Lindsey R Hammerslag; Timothy H C Cheung; Jeffrey Lenz; Robert H Mach; Robert R Luedtke; Janet L Neisewander
Journal:  Synapse       Date:  2013-07-17       Impact factor: 2.562

4.  Studies of new fused benzazepine as selective dopamine D3 receptor antagonists using 3D-QSAR, molecular docking and molecular dynamics.

Authors:  Jing Liu; Yan Li; Shuwei Zhang; Zhengtao Xiao; Chunzhi Ai
Journal:  Int J Mol Sci       Date:  2011-02-18       Impact factor: 5.923

5.  Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia.

Authors:  Pierre Sokoloff; Ludovic Leriche; Jorge Diaz; Jacques Louvel; René Pumain
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-09-22       Impact factor: 3.000

Review 6.  Effects of bisphenol-A and other endocrine disruptors compared with abnormalities of schizophrenia: an endocrine-disruption theory of schizophrenia.

Authors:  James S Brown
Journal:  Schizophr Bull       Date:  2008-01-31       Impact factor: 9.306

7.  Dopamine D3 Receptor Mediates Preadolescent Stress-Induced Adult Psychiatric Disorders.

Authors:  Joon H Seo; Eldo V Kuzhikandathil
Journal:  PLoS One       Date:  2015-11-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.